TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04629560
Drug: Miracle Fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures. Patients assigned to receive the miracle fruit will receive written instructions regarding the use of the fruit. Patients should put the fruit tablet or powder in the mouth and gently chew/suck to dissolve and cover the tongue with the powder
Study: NCT01773837
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (pill) p.o.
Study: NCT03527576
Drug: NaCl 0.0308 MEQ/ML Injectable Solution
Normalized name: Glucose 43 MG/ML / NaCl 0.0308 MEQ/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of NaCl 0.9% before the surgery.
Study: NCT00807950
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04095455
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion with similar rate and volume to KM infusion was used as a placebo.
Study: NCT02829879
Drug: 8% arginine/1450ppm sodium monofluorophosphate dentifrice
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04035785
Drug: Kangfu Anti-inflammatory Suppository
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.
Study: NCT01816139
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Cream applied to the vagina daily for 2 weeks followed by dosing 2 times a week for 10 weeks
Study: NCT01816139
Drug: WC3011 Estradiol Vaginal Cream
Normalized name: Estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: WC3011 estradiol vaginal cream applied daily for 2 weeks followed by dosing 2 times a week for 10 weeks
Study: NCT02078388
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01943006
Drug: Placebo cream without active substance
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03239015
Drug: PD-1/L1 inhibitor plus anti-angiogenic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/L1 inhibitor plus anti-angiogenic agent is a regimen used for refractory tumor without druggable target
Study: NCT03662100
Drug: LY3074828
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02229734
Drug: Androgen Suppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide 45mg every 6 months for a total of 18 months
Study: NCT01360996
Drug: 3 mg DRSP/20 μg EE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
Study: NCT00295269
Drug: Mythylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03883269
Drug: Clindamycin 1% topical lotion formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 1% topical lotion formulation, BID, 4 weeks
Study: NCT03883269
Drug: 70% topical ethanol solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70% topical ethanol solution, BID, 4 weeks
Study: NCT04522297
Drug: Nor-epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion norepinephrine
Study: NCT00016458
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01264939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
Study: NCT01454076
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 500 mg tablets (Cycle 1 only)
Study: NCT02653196
Drug: Keratinocyte Growth Factor
Normalized name: Keratinocyte growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: KGF 60 mcg/kg IV: 6 doses
Study: NCT02984176
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets of Placebo Tablets (one tablet after each meal) and to fast overnight the day before the operation.
Study: NCT01823029
Drug: enteral nutrition.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01823029
Drug: injection of iron
Normalized name: iron sucrose Injection
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01302964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to placebo will receive placebo for duration of the study
Study: NCT00136487
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02674412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic
Study: NCT02204254
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
Study: NCT02433834
Drug: Serevent Diskus 50 μg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02433834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00190060
Drug: Transdermal testosterone gel (Testogel 1% )
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel (Testogel 1% ), 50 mg/d for 6 months
Study: NCT00190060
Drug: Matched transdermal placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched transdermal placebo gel, 50mg/d for 6 months
Study: NCT03251326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT02209766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. st cohort: Dose 1(2g) D5884(n=3) in Japanese~2. nd cohort: Dose 2(4g) D5884(n=3) in Japanese
Study: NCT00596011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo BID
Study: NCT01099085
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 40 mg qd daily
Study: NCT01099085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02720926
Drug: Xeloda,
Normalized name: Xeloda, 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (xeloda): 2000mg/m2, twice a day on Day 1-14;
Study: NCT02720926
Drug: TKI258
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 dose levels of TKI258: 200mg, 300mg, 400mg, 500mg once daily, 5days on and 2 days off;
Study: NCT00796965
Drug: AZD7268
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution/Capsule, Oral, once daily
Study: NCT00796965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00239057
Drug: Enteric-Coated Mycophenolate Sodium
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00024362
Drug: BBR 3464
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02607488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight \[ideal body weight (IBW) + 0.4 × (actual body weight-IBW)\]
Study: NCT04613180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo containing no active substance
Study: NCT04659070
Drug: Experimental : Ezetimibe / Rosuvastatin + Telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10mg / Rosuvastatin 20mg + Telmisartan 80mg PO, Once daily for 8 weeks
Study: NCT04659070
Drug: Active comparator1 : Ezetimibe / Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10mg / Rosuvastatin 20mg PO, Once daily for 8 weeks
Study: NCT01113346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For children aged less than 1 y.o.: Placebo, 1/2 tablet 2 times a day for 7 days.~For children aged 1-4 y.o.: Placebo, 1 tablet 2 times a day for 7 days.
Study: NCT02081495
Drug: DOXIL/CAELYX reference product (Treatment A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive DOXIL/CAELYX reference product 50 mg/m2 as an intravenous (into a vein) infusion over 90 minutes on Day 1.
Study: NCT02081495
Drug: DOXIL/CAELYX test product (Treatment B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive DOXIL/CAELYX test product 50 mg/m2 as an intravenous infusion over 90 minutes on Day 1.
Study: NCT01595360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is applied directly to the bleeding site after tooth extraction
Study: NCT02896127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
Study: NCT01587742
Drug: CCB use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of CCB during the study period between January 1, 1996 to December 31, 2009. The CCBs administered to the patients include isradipine and lacidipine.
Study: NCT00552110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to MFNS given every morning and every evening x 2 weeks.
Study: NCT01628926
Drug: SPM 962
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Study: NCT02549027
Drug: MK-6096
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral MK-6096 tablets (5 mg strength)
Study: NCT02549027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
Study: NCT01628926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPM962-placebo patch and Ropinirole-placebo tab
Study: NCT00003141
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02700451
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Age 18-64: Intravenous Ketorolac 30 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.~Age 65-75: Intravenous Ketorolac 15 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
Study: NCT02700451
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Acetaminophen 1000mg every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
Study: NCT02700451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Normal Saline every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
Study: NCT02652624
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/10 mg FDC tablet administered orally once daily with food
Study: NCT02652624
Drug: E/C/F/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/300 mg FDC administered orally once daily with food
Study: NCT02652624
Drug: RTV
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTV 100 mg tablets administered orally once daily with food
Study: NCT02652624
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/300 mg tablet administered orally once daily with food
Study: NCT02652624
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/200/25 mg FDC tablet administered orally once daily without regard to food
Study: NCT01672957
Drug: Immunosuppressive Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol does not specify any particular immunosuppressive drug and regimen for treatment. The choice of immunosuppressive therapy will be made prior to enrollment by the treating physician.
Study: NCT00714779
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-40 mg / day orally
Study: NCT01766375
Drug: Cyclosporin A,mycophenolate mofetil,Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
Study: NCT04554433
Drug: Ethanol with Asprin
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group ( A ) which will receive the new protocol will be categorized into sub-groups according to the medical conditions , inclusion criteria , investigations and symptoms .~1. Inhaling alcohol vapor through nostrils .~2. Inhalation of Alcohol vapor driven by Oxygen .~3. Inhalation of Alcohol vapor driven by oxygen in case of ARDS.~4. Ethyl Alcohol infusion into the airway . Investigations will be made before starting the protocol and follow up data will be collected every day .~Follow up test will be done according to the schedule . PCR test will be done according to the duration of each technique to evaluate the final results .
Study: NCT02103478
Drug: ASTX727 Dose Confirmation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization cross over design for courses 1 and 2
Study: NCT02103478
Drug: ASTX727 Fixed-Dose Combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose investigational product
Study: NCT00666367
Drug: D-cure
Normalized name: Cocci-Cure C for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of D-cure (SMB oral intake) in syringe Exacta-Med Oral Dispenser.
Study: NCT00666367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of Arachidis oleum raffinatum Ph. Eur. in syringe Med Oral Dispenser.
Study: NCT02357576
Drug: Intralipid 20% I.V. Fat Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01014507
Drug: 8 cycles BEACOPPesc plus oral contraceptive
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03101709
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
Study: NCT00902356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
Study: NCT00691236
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4mg IV 3 weekly for 6 doses
Study: NCT00691236
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin + Cisplatinum and Ifosfamide
Study: NCT03304379
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasinumab-matching placebo (solution for injection in pre-filled syringe); NSAID-matching placebo (capsule)
Study: NCT00617240
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks
Study: NCT02003625
Drug: meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02003625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01140425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution once daily x 7 days
Study: NCT01087424
Drug: R mini CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 40 mg/m2 D1 D2 D3 D4 D5 Rituximab 375 mg/m2 D1 Doxorubicine 25 mg/m2 D1 Cyclophosphamide 400 mg/m2 D1 Vincristine 1 mg/m2 D1
Study: NCT02271945
Drug: MEDI-551 12 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13
Study: NCT02455076
Drug: Rapid-acting insulin analogs
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the BG levels are \>140 mg/dL, rapid acting insulin analogs will be administered following the supplemental/sliding scale protocol. If a patient is able and expected to eat all or most of his/her meals, supplemental insulin will be administered before each meal and at bedtime following the usual dose of the sliding scale protocol. If a patient is not able to eat, supplemental insulin will be administered every 6 hours following the sensitive dose of the sliding scale. If the BG is 141-180 mg/dL, then 2,3 or 4 units of insulin will be given; for BG 181 - 220 mg/dL; the units of insulin will be 3, 4 or 6; for BG 221 - 260 mg/dL, the units of insulin will be 4,5 or 8; for BG 261 - 300 mg/dL, the units of insulin will be 5, 6 or 10; for BG 301 - 350, the insulin will be 6, 8 or 12 units; for BG 351 - 400 mg/dL, the units of insulin will be 7,10 or 14; for BG\> 400 mg/dL, the insulin will be 8,12 or 16 units.
Study: NCT00627679
Drug: MAP0010 intermediate dose
Normalized name: PREVOTELLA INTERMEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
Study: NCT00409292
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally daily for as long as the participant continues to receive a benefit.
Study: NCT01430065
Drug: ASP015K
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01020019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control
Study: NCT01918475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml of NaCl 0.9% is administered intravenously
Study: NCT01121211
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone 300mcg transdermal patch x 24 weeks.
Study: NCT01121211
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal patch x 24 weeks
Study: NCT03251248
Drug: MSB11455
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.
Study: NCT01557075
Drug: Pravastatin (High dose statin treatment)
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~Pravastatin 20mg daily for 12 months after randomization
Study: NCT02867306
Drug: ASP1707
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02867306
Drug: methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT02597062
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04040192
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle ointment
Study: NCT00576316
Drug: Symbicort Turbuhaler 160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01013558
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.15 microgram/kg/min continuous infusion.
Study: NCT03016819
Drug: AL3818
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
Study: NCT01930058
Drug: MK-8876
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.
Study: NCT01971658
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01971658
Drug: Velcade®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01898793
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01328457
Drug: Paromomycin sulfate
Normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin IM Injection, 11 mg/kg as the base, intramuscular, once a day on 21 consecutive days (or no more than 22 days if one injection is missed during the treatment period).
Study: NCT03196219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varnish Placebo
Study: NCT01126580
Drug: LY2189265
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01126580
Drug: Placebo (oral)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01126580
Drug: Placebo (subcutaneous)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02770157
Drug: Genotropin®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00827892
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
Study: NCT02485119
Drug: BAY94-9343
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: 4.5 mg/kg of BAY 94-9343 at Q3W dose regimen. Cohort 2: 6.5 mg/kg of BAY 94-9343 at Q3W dose regimen.
Study: NCT01769157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03860896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04527068
Drug: Tripleitriumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg intravenously every 3week
Study: NCT01714466
Drug: NER1006
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00084695
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV